Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.
Mouth-Watering Possibilities in Sjögren’s Disease
New ACR guidelines for SARD-associated interstitial lung disease cover key recommendations for screening, monitoring and first-line treatment options.
Sjögren’s Disease: More Than Just a Syndrome
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
How to Diagnose Sjögren’s Disease
Improve your Sjögren’s disease diagnosis. Experts discuss objective testing, seronegative cases, ILD screening & management strategies.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
10 Ways to Manage Dry Mouth
This article discusses 10 expert tips for mitigating dry mouth, a common symptom of Sjögren’s disease & other rheumatic conditions.
Guidelines for ILD in Systemic Autoimmune Rheumatic Disease
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
New Review Article Explores Endotyping, B Cells & More
A case-based review examines B cells in Sjögren’s disease, the use of endotyping for patient stratification & prognostication, & lymphoma risk.
- 1
- 2
- 3
- …
- 828
- Next Page »